Clinical trial · Observational
The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT
The Performance of Uroepithelial Cancer Risk Genes in the Necessity of Secondary Transurethral Resection of Bladder Tumor for High-risk Non-muscle-invasive Bladder Cancer: A Multicenter Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators performed the Genetron Uro V1 test on the urine of patients before secondary TURBT and compared it with the final pathological results. To analyze the performance of the Genetron Uro V1 method in a study to predict the need for secondary TURBT in high-risk NMIBC patients and the correlation with patient's RFS and OS.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Concordance analysis of Genetron Uro V1 assay results with gold standard results of secondary TURBT histopathology
- timeFrame
- Through study completion, an average of 1 year
- description
- Through Concordance analysis of Genetron Uro V1 assay results with gold standard results of secondary TURBT histopathology, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of Genetron Uro V1 detected before secondary TURBT are measured.
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 2 years after surgery
- description
- To analyze the performance of the Genetron Uro V1 method in a study to predict the correlation with patient OS.
- measure
- Recurrence-free survival
- timeFrame
- 2 years after surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with a confirmed diagnosis of high-risk NMIBC at each study center: including (1) inadequate first TURBT; (2) absence of muscle tissue in the first TURBT specimen, except for TaG1 and carcinoma in situ alone; (3) stage T1 tumors; (4) grade G3 tumors, except for carcinoma in situ alone; (5) TaG1G2 meeting both multiple, recurrent, and \>3 cm in diameter (or low-grade urothelial epithelial carcinoma) 2. gender is not limited. 3. age ≥ 18 years old. 4. the ability to provide a 100 ml standing urine sample within 3-6 weeks after the first TURBT and before the secondary transurethral resection. 5. agree to provide basic personal clinical information and pathological and imaging data for use in scientific research and sign an informed consent form related to scientific research. 6. consent to perform the genetic testing services involved in the trial. 7. agree to provide monitoring results in the follow-up relapse monitoring process. Exclusion Criteria: 1. patients with other non-uroepithelial malignancies (including prostate cancer and renal cell carcinoma). 2. patients who failed to undergo secondary transurethral resection. 3. patients with incomplete information on sample pathology. 4. patients with contaminated samples. 5. Patients whose urine samples fail quality control and cannot be re-sampled for valid reasons. 6. Patients whose samples cannot complete the test due to reasonable cause. 7. any condition that, in the opinion of the investigator, may harm the subject or cause the subject to be unable to meet or perform the requirements of the study. 8. Patients who are unable to provide written informed consent.
References
Publications (0)
Data not yet available